Floatz logo

lx1001

Alzheimer Disease

Lexeo Therapeuticsgene_therapyPhase 1/2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
65/ 100

Competitive context

316 Active assets in the Alzheimer Disease cohort.

Asset / SponsorPhaseRating
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Akiva Mintz
Phase 4BBB
Namenda
Carnot Laboratories
Phase 4BBB
Cipralex
NYU Langone Health
Phase 4BBB
Rivastigmine
Anhui Provincial Hospital
Phase 4BBB
Sertraline
AstraZeneca
Phase 4BBB

View all 50 →

Same molecule, other indications

lx1001 is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →